Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia

Purpose:to study the hemodynamics of the bulbar conjunctiva in patients with dyslipidemia and a history of COVID-19 associated pneumonia who received etiopathogenetic therapy. Material and methods. 54 patients (108 eyes) aged 61 ± 14 with a documented diagnosis of COVID-19-associated pneumonia and dyslipidemia were prospectively examined 3 months after the discharge from hospital. Patients were divided into two groups, identical in gender and age, depending on the presence or absence of metabolic syndrome. For 1 month, both groups received etiotropic therapy: statins, antioxidants thioctic acid pills and topical antioxidant instillations (1 % solution of Emoxipine®three times a day, and instillations of NSAID Broxinac®(in the form of 0.09 % Bromfenacum eyedrops) 1 drop 2 times a day. Results.Improvement was achieved in perivascular parameters (of 54 % of patients of group 1 and 50 % of patients of group 2); in the shape of bloodvessels (in 10 and 11 % of cases, respectively); intravascular parameters (in 71 and 78 %, respectively). Conclusion. The proposed etiopathogenetic therapy has a positive effect on the state of damaged bulbar conjunctiva microcirculation.

Modern Approaches to the Technology of Tablet Dosage Forms of Thioctic Acid (Review)

Introduction. Thioctic (α-lipoic) acid is an endogenous antioxidant and is used for liver diseases, poisoning with salts of heavy metals, hyperlipidemia, atherosclerotic heart disease, neuropathy, insulin-resistant forms of diabetes mellitus, etc. technologies for producing tableted medicinal preparations of thioctic acid, necessary for the pharmaceutical development of thioctic acid tablets at pharmaceutical industry enterprises.Text. The review considers the physicochemical properties of the pharmaceutical substance thioctic acid, the features of its pharmaceutical and technological properties, and compatibility with excipients. In the technology of thioctic acid tablets, methods of direct compression and compression with preliminary wet granulation, including those using organic solvents, are used. To increase photostability, thioctic acid tablets are coated. Information on excipients in the composition of core tablets and film coat of thioctic acid tablets registered in Russia is presented. The problems of tabletting thioctic acid are described: sintering of the granulate during the drying process, adhesion of the tabletting mass to the pressing tool and the resulting unevenness of the tablet surface. The ways of optimizing the tabletting process of thioctic acid using various compositions of excipients, improving the flowability of a pharmaceutical substance both during its synthesis and as a result of technological processing, choosing the optimal modes of granulation, drying, pressing are considered.Conclusion. As a result of the analysis of the literature data, the features of the technology for producing thioctic acid tablets were revealed, which are due to the high content of the pharmaceutical substance in tablets (up to 600 mg), the need to use a minimum amount of excipients (from 27 to 51 %), poor flowability, and low melting point of the pharmaceutical substance. Improvement of compressibility and prevention of adhesion can be achieved by using the pharmaceutical substance thioctic acid of a certain granulometric composition, auxiliary substances of the basic nature and a high content of glidants (up to 6 %). The identified manufacturing features should be taken into account in the pharmaceutical development of thioctic acid tablets.